Aceruloplasminemia. An Update

International Review of Neurobiology

Volumn 110, Issue , 2013, Pages 125-151

  Kono, Satoshi ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Ceruloplasmin; Ferroxidase; GPI; Iron; Mutation; Neurodegeneration with brain iron accumulation (NBIA); Pathology; Radical injury

Indexed keywords

CERULOPLASMIN; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FRESH FROZEN PLASMA; IRON;

ACERULOPLASMINEMIA; ARTICLE; BIOACCUMULATION; BRAIN REGION; CERULOPLASMIN GENE; CLINICAL FEATURE; DEGENERATIVE DISEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG EFFECT; EXPERIMENTAL ANIMAL; GENE; GENE FUNCTION; GENE IDENTIFICATION; HOMEOSTASIS; HUMAN; IRON METABOLISM; IRON THERAPY; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NERVE DEGENERATION; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION;

CERULOPLASMIN; FERROXIDASE; GPI; IRON; MUTATION; NEURODEGENERATION WITH BRAIN IRON ACCUMULATION (NBIA); PATHOLOGY; RADICAL INJURY;

ANIMALS; BRAIN; CERULOPLASMIN; HUMANS; IRON; IRON METABOLISM DISORDERS; MUTATION; NEURODEGENERATIVE DISEASES;

EID: 84887253073     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-410502-7.00007-7     Document Type: Chapter

References (99)

1. Bartnikas T.B., Gitlin J.D. How to make a metalloprotein. Nature Structural Biology 2001, 8(9):733-734.
2. Bento I., Peixoto C., Zaitsev V.N., Lindley P.F. Ceruloplasmin revisited: Structural and functional roles of various metal cation-binding sites [research support, Non-U.S. Gov't]. Acta Crystallographica Section D: Biological Crystallography 2007, 63(Pt 2):240-248.
3. Bethlehem C., van Harten B., Hoogendoorn M. Central nervous system involvement in a rare genetic iron overload disorder [case reports]. The Netherlands Journal of Medicine 2010, 68(10):316-318.
4. Bosio S., De Gobbi M., Roetto A., Zecchina G., Leonardo E., Rizzetto M., et al. Anemia and iron overload due to compound heterozygosity for novel ceruloplasmin mutations. Blood 2002, 100(6):2246-2248.
5. Daimon M., Kato T., Kawanami T., Tominaga M., Igarashi M., Yamatani K., et al. A nonsense mutation of the ceruloplasmin gene in hereditary ceruloplasmin deficiency with diabetes mellitus [case reports]. Biochemical and Biophysical Research Communications 1995, 217(1):89-95.
6. Daimon M., Susa S., Ohizumi T., Moriai S., Kawanami T., Hirata A., et al. A novel mutation of the ceruloplasmin gene in a patient with heteroallelic ceruloplasmin gene mutation (HypoCPGM). The Tohoku Journal of Experimental Medicine 2000, 191(3):119-125.
7. De Domenico I., Ward D.M., di Patti M.C., Jeong S.Y., David S., Musci G., et al. Ferroxidase activity is required for the stability of cell surface ferroportin in cells expressing GPI-ceruloplasmin. The EMBO Journal 2007, 26(12):2823-2831.
8. di Patti M.C., Maio N., Rizzo G., De Francesco G., Persichini T., Colasanti M., et al. Dominant mutants of ceruloplasmin impair the copper loading machinery in aceruloplasminemia. The Journal of Biological Chemistry 2009, 284(7):4545-4554.
9. Donangelo C.M., Woodhouse L.R., King S.M., Viteri F.E., King J.C. Supplemental zinc lowers measures of iron status in young women with low iron reserves. Journal of Nutrition 2002, 132(7):1860-1864.
10. Fasano A., Bentivoglio A.R., Colosimo C. Movement disorder due to aceruloplasminemia and incorrect diagnosis of hereditary hemochromatosis. Journal of Neurology 2007, 254(1):113-114.
11. Fasano A., Colosimo C., Miyajima H., Tonali P.A., Re T.J., Bentivoglio A.R. Aceruloplasminemia: A novel mutation in a family with marked phenotypic variability. Movement Disorders 2008, 23(5):751-755.
12. Finkenstedt A., Wolf E., Hofner E., Gasser B.I., Bosch S., Bakry R., et al. Hepatic but not brain iron is rapidly chelated by deferasirox in aceruloplasminemia due to a novel gene mutation. Journal of Hepatology 2010, 53(6):1101-1107.
13. Fox P.L., Mazumder B., Ehrenwald E., Mukhopadhyay C.K. Ceruloplasmin and cardiovascular disease. Free Radical Biology & Medicine 2000, 28(12):1735-1744.
14. Gitlin J.D. Wilson disease. Gastroenterology 2003, 125(6):1868-1877.
15. Guo P., Cui R., Chang Y.Z., Wu W.S., Qian Z.M., Yoshida K., et al. Hepcidin, an antimicrobial peptide is downregulated in ceruloplasmin-deficient mice. Peptides 2009, 30(2):262-266.
16. Haack T.B., Hogarth P., Kruer M.C., Gregory A., Wieland T., Schwarzmayr T., et al. Exome sequencing reveals de novo WDR45 mutations causing a phenotypically distinct, X-linked dominant form of NBIA. The American Journal of Human Genetics 2012, 91(6):1144-1149.
17. Haemers I., Kono S., Goldman S., Gitlin J.D., Pandolfo M. Clinical, molecular, and PET study of a case of aceruloplasminaemia presenting with focal cranial dyskinesia. Journal of Neurology, Neurosurgery & Psychiatry 2004, 75(2):334-337.
18. Hahn P., Qian Y., Dentchev T., Chen L., Beard J., Harris Z.L., et al. Disruption of ceruloplasmin and hephaestin in mice causes retinal iron overload and retinal degeneration with features of age-related macular degeneration. Proceedings of the National Academy of Sciences of the United States of America 2004, 101(38):13850-13855.
19. Harris Z.L., Durley A.P., Man T.K., Gitlin J.D. Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron efflux. Proceedings of the National Academy of Sciences of the United States of America 1999, 96(19):10812-10817.
20. Harris Z.L., Migas M.C., Hughes A.E., Logan J.I., Gitlin J.D. Familial dementia due to a frameshift mutation in the caeruloplasmin gene. QJM 1996, 89:355-359.
21. Harris Z.L., Takahashi Y., Miyajima H., Serizawa M., MacGillivray R.T., Gitlin J.D. Aceruloplasminemia: Molecular characterization of this disorder of iron metabolism. Proceedings of the National Academy of Sciences of the United States of America 1995, 92(7):2539-2543.
22. Hatanaka Y., Okano T., Oda K., Yamamoto K., Yoshida K. Aceruloplasminemia with juvenile-onset diabetes mellitus caused by exon skipping in the ceruloplasmin gene. Internal Medicine 2003, 42(7):599-604.
23. Hellman N.E., Gitlin J.D. Ceruloplasmin metabolism and function. Annual Review of Nutrition 2002, 22:439-458.
24. Hellman N.E., Kono S., Mancini G.M., Hoogeboom A.J., De Jong G.J., Gitlin J.D. Mechanisms of copper incorporation into human ceruloplasmin. The Journal of Biological Chemistry 2002, 277(48):46632-46638.
25. Hellman N.E., Kono S., Miyajima H., Gitlin J.D. Biochemical analysis of a missense mutation in aceruloplasminemia. The Journal of Biological Chemistry 2002, 277(2):1375-1380.
26. Hellman N.E., Schaefer M., Gehrke S., Stegen P., Hoffman W.J., Gitlin J.D., et al. Hepatic iron overload in aceruloplasminaemia. Gut 2000, 47(6):858-860.
27. Hida A., Kowa H., Iwata A., Tanaka M., Kwak S., Tsuji S. Aceruloplasminemia in a Japanese woman with a novel mutation of CP gene: Clinical presentations and analysis of genetic and molecular pathogenesis. Journal of Neurological Sciences 2010, 298(1-2):136-139.
28. Hineno A., Kaneko K., Yoshida K., Ikeda S. Ceruloplasmin protects against rotenone-induced oxidative stress and neurotoxicity. Neurochemical Research 2011, 36(11):2127-2135.
29. Jeong S.Y., David S. Glycosylphosphatidylinositol-anchored ceruloplasmin is required for iron efflux from cells in the central nervous system. The Journal of Biological Chemistry 2003, 278(29):27144-27148.
30. Jeong S.Y., David S. Age-related changes in iron homeostasis and cell death in the cerebellum of ceruloplasmin-deficient mice. Journal of Neuroscience 2006, 26(38):9810-9819.
31. Kalman B., Lautenschlaeger R., Kohlmayer F., Buchner B., Kmiec T., Klopstock T., et al. An international registry for neurodegeneration with brain iron accumulation. Orphanet Journal of Rare Diseases 2012, 7:66.
32. Kaneko K., Hineno A., Yoshida K., Ohara S., Morita H., Ikeda S. Extensive brain pathology in a patient with aceruloplasminemia with a prolonged duration of illness. Human Pathology 2012, 43(3):451-456.
33. Kaneko Y., Miyajima H., Piperno A., Tomosugi N., Hayashi H., Morotomi N., et al. Measurement of serum hepcidin-25 levels as a potential test for diagnosing hemochromatosis and related disorders. Journal of Gastroenterology 2010, 45(11):1163-1171.
34. Kaneko K., Nakamura A., Yoshida K., Kametani F., Higuchi K., Ikeda S. Glial fibrillary acidic protein is greatly modified by oxidative stress in aceruloplasminemia brain. Free Radical Research 2002, 36(3):303-306.
35. Kaneko K., Yoshida K., Arima K., Ohara S., Miyajima H., Kato T., et al. Astrocytic deformity and globular structures are characteristic of the brains of patients with aceruloplasminemia. Journal of Neuropathology and Experimental Neurology 2002, 61(12):1069-1077.
36. Kato T., Daimon M., Kawanami T., Ikezawa Y., Sasaki H., Maeda K. Islet changes in hereditary ceruloplasmin deficiency. Human Pathology 1997, 28(4):499-502.
37. Kawanami T., Kato T., Daimon M., Tominaga M., Sasaki H., Maeda K., et al. Hereditary caeruloplasmin deficiency: Clinicopathological study of a patient. Journal of Neurology, Neurosurgery & Psychiatry 1996, 61(5):506-509.
38. Ke Y., Ming Qian Z. Iron misregulation in the brain: A primary cause of neurodegenerative disorders. Lancet Neurology 2003, 2(4):246-253.
39. Klomp L.W., Farhangrazi Z.S., Dugan L.L., Gitlin J.D. Ceruloplasmin gene expression in the murine central nervous system. Journal of Clinical Investigation 1996, 98(1):207-215.
40. Kohno S., Miyajima H., Takahashi Y., Inoue Y. Aceruloplasminemia with a novel mutation associated with parkinsonism. Neurogenetics 2000, 2(4):237-238.
41. Kohno S., Miyajima H., Takahashi Y., Suzuki H., Hishida A. Defective electron transfer in complexes I and IV in patients with aceruloplasminemia. Journal of Neurological Sciences 2000, 182(1):57-60.
42. Kono S., Suzuki H., Oda T., Miyajima H., Takahashi Y., Shirakawa K., et al. Biochemical features of ceruloplasmin gene mutations linked to aceruloplasminemia. Neuromolecular Medicine 2006, 8(3):361-374.
43. Kono S., Suzuki H., Oda T., Shirakawa K., Takahashi Y., Kitagawa M., et al. Cys-881 is essential for the trafficking and secretion of truncated mutant ceruloplasmin in aceruloplasminemia. Journal of Hepatology 2007, 47(6):844-850.
44. Kono S., Suzuki H., Takahashi K., Takahashi Y., Shirakawa K., Murakawa Y., et al. Hepatic iron overload associated with a decreased serum ceruloplasmin level in a novel clinical type of aceruloplasminemia. Gastroenterology 2006, 131(1):240-245.
45. Kono S., Yoshida K., Tomosugi N., Terada T., Hamaya Y., Kanaoka S., et al. Biological effects of mutant ceruloplasmin on hepcidin-mediated internalization of ferroportin. Biochimica et Biophysica Acta 2010, 1802(11):968-975.
46. Kuhn J., Bewermeyer H., Miyajima H., Takahashi Y., Kuhn K.F., Hoogenraad T.U. Treatment of symptomatic heterozygous aceruloplasminemia with oral zinc sulphate. Brain & Development 2007, 29(7):450-453.
47. Kuhn J., Miyajima H., Takahashi Y., Kunath B., Hartmann-Klosterkoetter U., Cooper-Mahkorn D., et al. Extrapyramidal and cerebellar movement disorder in association with heterozygous ceruloplasmin gene mutation. Journal of Neurology 2005, 252(1):111-113.
48. Loreal O., Turlin B., Pigeon C., Moisan A., Ropert M., Morice P., et al. Aceruloplasminemia: New clinical, pathophysiological and therapeutic insights. Journal of Hepatology 2002, 36(6):851-856.
49. Mariani R., Arosio C., Pelucchi S., Grisoli M., Piga A., Trombini P., et al. Iron chelation therapy in aceruloplasminaemia: Study of a patient with a novel missense mutation. Gut 2004, 53(5):756-758.
50. McNeill A., Birchall D., Hayflick S.J., Gregory A., Schenk J.F., Zimmerman E.A., et al. T2* and FSE MRI distinguishes four subtypes of neurodegeneration with brain iron accumulation. Neurology 2008, 70(18):1614-1619.
51. McNeill A., Pandolfo M., Kuhn J., Shang H., Miyajima H. The neurological presentation of ceruloplasmin gene mutations. European Neurology 2008, 60(4):200-205.
52. Mittal B., Doroudchi M.M., Jeong S.Y., Patel B.N., David S. Expression of a membrane-bound form of the ferroxidase ceruloplasmin by leptomeningeal cells. Glia 2003, 41(4):337-346.
53. Miyajima H. Aceruloplasminemia, an iron metabolic disorder. Neuropathology 2003, 23(4):345-350.
54. Miyajima H., Adachi J., Kohno S., Takahashi Y., Ueno Y., Naito T. Increased oxysterols associated with iron accumulation in the brains and visceral organs of acaeruloplasminaemia patients. QJM 2001, 94(8):417-422.
55. Miyajima H., Fujimoto M., Kohno S., Kaneko E., Gitlin J.D. CSF abnormalities in patients with aceruloplasminemia. Neurology 1998, 51(4):1188-1190.
56. Miyajima H., Kohno S., Takahashi Y., Yonekawa O., Kanno T. Estimation of the gene frequency of aceruloplasminemia in Japan. Neurology 1999, 53(3):617-619.
57. Miyajima H., Kono S., Takahashi Y., Sugimoto M. Increased lipid peroxidation and mitochondrial dysfunction in aceruloplasminemia brains. Blood Cells, Molecules & Diseases 2002, 29(3):433-438.
58. Miyajima H., Kono S., Takahashi Y., Sugimoto M., Sakamoto M., Sakai N. Cerebellar ataxia associated with heteroallelic ceruloplasmin gene mutation. Neurology 2001, 57(12):2205-2210.
59. Miyajima H., Nishimura Y., Mizoguchi K., Sakamoto M., Shimizu T., Honda N. Familial apoceruloplasmin deficiency associated with blepharospasm and retinal degeneration. Neurology 1987, 37(5):761-767.
60. Miyajima H., Takahashi Y., Kamata T., Shimizu H., Sakai N., Gitlin J.D. Use of desferrioxamine in the treatment of aceruloplasminemia. Annals of Neurology 1997, 41(3):404-407.
61. Miyajima H., Takahashi Y., Kono S., Hishida A., Ishikawa K., Sakamoto M. Frontal lobe dysfunction associated with glucose hypometabolism in aceruloplasminemia. Journal of Neurology 2005, 252(8):996-997.
62. Miyajima H., Takahashi Y., Kono S., Sugimoto M., Suzuki Y., Hishida A., et al. Glucose and oxygen hypometabolism in aceruloplasminemia brains. Internal Medicine 2002, 41(3):186-190.
63. Miyajima H., Takahashi Y., Serizawa M., Kaneko E., Gitlin J.D. Increased plasma lipid peroxidation in patients with aceruloplasminemia. Free Radical Biology & Medicine 1996, 20(5):757-760.
64. Morita H., Ikeda S., Yamamoto K., Morita S., Yoshida K., Nomoto S., et al. Hereditary ceruloplasmin deficiency with hemosiderosis: A clinicopathological study of a Japanese family. Annals of Neurology 1995, 37(5):646-656.
65. Mostad E.J., Prohaska J.R. Glycosylphosphatidylinositol-linked ceruloplasmin is expressed in multiple rodent organs and is lower following dietary copper deficiency. Experimental Biology and Medicine (Maywood, NJ) 2011, 236(3):298-308.
66. Muroi R., Yagyu H., Kobayashi H., Nagata M., Sato N., Ideno J., et al. Early onset insulin-dependent diabetes mellitus as an initial manifestation of aceruloplasminaemia. Diabetic Medicine 2006, 23(10):1136-1139.
67. Nemeth E., Tuttle M.S., Powelson J., Vaughn M.B., Donovan A., Ward D.M., et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004, 306(5704):2090-2093.
68. Ogimoto M., Anzai K., Takenoshita H., Kogawa K., Akehi Y., Yoshida R., et al. Criteria for early identification of aceruloplasminemia. Internal Medicine 2011, 50(13):1415-1418.
69. Oide T., Yoshida K., Kaneko K., Ohta M., Arima K. Iron overload and antioxidative role of perivascular astrocytes in aceruloplasminemia. Neuropathology and Applied Neurobiology 2006, 32(2):170-176.
70. Okamoto N., Wada S., Oga T., Kawabata Y., Baba Y., Habu D., et al. Hereditary ceruloplasmin deficiency with hemosiderosis. Human Genetics 1996, 97(6):755-758.
71. Osaki S., Johnson D.A., Frieden E. The possible significance of the ferrous oxidase activity of ceruloplasmin in normal human serum. The Journal of Biological Chemistry 1966, 241(12):2746-2751.
72. Pan P.L., Tang H.H., Chen Q., Song W., Shang H.F. Desferrioxamine treatment of aceruloplasminemia: Long-term follow-up. Movement Disorders 2011, 26(11):2142-2144.
73. Patel B.N., David S. A novel glycosylphosphatidylinositol-anchored form of ceruloplasmin is expressed by mammalian astrocytes. The Journal of Biological Chemistry 1997, 272(32):20185-20190.
74. Patel B.N., Dunn R.J., David S. Alternative RNA splicing generates a glycosylphosphatidylinositol-anchored form of ceruloplasmin in mammalian brain. The Journal of Biological Chemistry 2000, 275(6):4305-4310.
75. Patel B.N., Dunn R.J., Jeong S.Y., Zhu Q., Julien J.P., David S. Ceruloplasmin regulates iron levels in the CNS and prevents free radical injury. Journal of Neuroscience 2002, 22(15):6578-6586.
76. Perez-Aguilar F., Burguera J.A., Benlloch S., Berenguer M., Rayon J.M. Aceruloplasminemia in an asymptomatic patient with a new mutation. Diagnosis and family genetic analysis. Journal of Hepatology 2005, 42(6):947-949.
77. Powell S.R. The antioxidant properties of zinc. Journal of Nutrition 2000, 130(5S Suppl.):1447S-1454S.
78. Ragan H.A., Nacht S., Lee G.R., Bishop C.R., Cartwright G.E. Effect of ceruloplasmin on plasma iron in copper-deficient swine. American Journal of Physiology 1969, 217(5):1320-1323.
79. Roberti Mdo R., Borges Filho H.M., Goncalves C.H., Lima F.L. Aceruloplasminemia: A rare disease-diagnosis and treatment of two cases. Revista Brasileira de Hematologia e Hemoterapia 2011, 33(5):389-392.
80. Salzer J.L., Lovejoy L., Linder M.C., Rosen C. Ran-2, a glial lineage marker, is a GPI-anchored form of ceruloplasmin. Journal of Neuroscience Research 1998, 54(2):147-157.
81. Samokyszyn V.M., Miller D.M., Reif D.W., Aust S.D. Inhibition of superoxide and ferritin-dependent lipid peroxidation by ceruloplasmin. The Journal of Biological Chemistry 1989, 264(1):21-26.
82. Sato M., Gitlin J.D. Mechanisms of copper incorporation during the biosynthesis of human ceruloplasmin. The Journal of Biological Chemistry 1991, 266(8):5128-5134.
83. Scheinberg I.H., Gitlin D. Deficiency of ceruloplasmin in patients with hepatolenticular degeneration (Wilson's disease). Science 1952, 116(3018):484-485.
84. Schulz K., Vulpe C.D., Harris L.Z., David S. Iron efflux from oligodendrocytes is differentially regulated in gray and white matter. Journal of Neuroscience 2011, 31(37):13301-13311.
85. Shang H.F., Jiang X.F., Burgunder J.M., Chen Q., Zhou D. Novel mutation in the ceruloplasmin gene causing a cognitive and movement disorder with diabetes mellitus. Movement Disorders 2006, 21(12):2217-2220.
86. Skidmore F.M., Drago V., Foster P., Schmalfuss I.M., Heilman K.M., Streiff R.R. Aceruloplasminaemia with progressive atrophy without brain iron overload: Treatment with oral chelation. Journal of Neurology, Neurosurgery & Psychiatry 2008, 79(4):467-470.
87. Summers M.R., Jacobs A., Tudway D., Perera P., Ricketts C. Studies in desferrioxamine and ferrioxamine metabolism in normal and iron-loaded subjects. British Journal of Haematology 1979, 42(4):547-555.
88. Takahashi Y., Miyajima H., Shirabe S., Nagataki S., Suenaga A., Gitlin J.D. Characterization of a nonsense mutation in the ceruloplasmin gene resulting in diabetes and neurodegenerative disease. Human Molecular Genetics 1996, 5(1):81-84.
89. Takeuchi Y., Yoshikawa M., Tsujino T., Kohno S., Tsukamoto N., Shiroi A., et al. A case of aceruloplasminaemia: Abnormal serum ceruloplasmin protein without ferroxidase activity. Journal of Neurology, Neurosurgery & Psychiatry 2002, 72(4):543-545.
90. Texel S.J., Xu X., Harris Z.L. Ceruloplasmin in neurodegenerative diseases. Biochemical Society Transactions 2008, 36(Pt 6):1277-1281.
91. Vachette P., Dainese E., Vasyliev V.B., Di Muro P., Beltramini M., Svergun D.I., et al. A key structural role for active site type 3 copper ions in human ceruloplasmin. The Journal of Biological Chemistry 2002, 277(43):40823-40831.
92. Vulpe C.D., Kuo Y.M., Murphy T.L., Cowley L., Askwith C., Libina N., et al. Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse. Nature Genetics 1999, 21(2):195-199.
93. Yamamoto K., Yoshida K., Miyagoe Y., Ishikawa A., Hanaoka K., Nomoto S., et al. Quantitative evaluation of expression of iron-metabolism genes in ceruloplasmin-deficient mice. Biochimica et Biophysica Acta 2002, 1588(3):195-202.
94. Yang F., Naylor S.L., Lum J.B., Cutshaw S., McCombs J.L., Naberhaus K.H., et al. Characterization, mapping, and expression of the human ceruloplasmin gene. Proceedings of the National Academy of Sciences of the United States of America 1986, 83(10):3257-3261.
95. Yazaki M., Yoshida K., Nakamura A., Furihata K., Yonekawa M., Okabe T., et al. A novel splicing mutation in the ceruloplasmin gene responsible for hereditary ceruloplasmin deficiency with hemosiderosis. Journal of Neurological Sciences 1998, 156(1):30-34.
96. Yonekawa M., Okabe T., Asamoto Y., Ohta M. A case of hereditary ceruloplasmin deficiency with iron deposition in the brain associated with chorea, dementia, diabetes mellitus and retinal pigmentation: Administration of fresh-frozen human plasma. European Neurology 1999, 42(3):157-162.
97. Yoshida K., Furihata K., Takeda S., Nakamura A., Yamamoto K., Morita H., et al. A mutation in the ceruloplasmin gene is associated with systemic hemosiderosis in humans. Nature Genetics 1995, 9(3):267-272.
98. Yoshida K., Kaneko K., Miyajima H., Tokuda T., Nakamura A., Kato M., et al. Increased lipid peroxidation in the brains of aceruloplasminemia patients. Journal of Neurological Sciences 2000, 175(2):91-95.
99. Zecca L., Youdim M.B., Riederer P., Connor J.R., Crichton R.R. Iron, brain ageing and neurodegenerative disorders. Nature Reviews Neuroscience 2004, 5(11):863-873.